| P50 | author | Elizabeth O. Hexner | Q85544163 |
| P2093 | author name string | Daria Babushok | |
| P2860 | cites work | ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression | Q24296658 |
| | Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT | Q24685958 |
| | Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). | Q33393151 |
| | DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 |
| | Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis | Q33400683 |
| | Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years | Q33517074 |
| | Outcome of transplantation for myelofibrosis | Q34015474 |
| | Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age. | Q35608022 |
| | IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F | Q35835653 |
| | The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation | Q35849342 |
| | How to manage the transplant question in myelofibrosis | Q35865676 |
| | One thousand patients with primary myelofibrosis: the mayo clinic experience | Q36512816 |
| | JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse | Q36805838 |
| | Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis | Q37163487 |
| | Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 |
| | Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis | Q37301516 |
| | Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes | Q37504482 |
| | Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia | Q37513369 |
| | Allogeneic stem cell transplantation for myelofibrosis in 2012. | Q37998567 |
| | Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors | Q38018908 |
| | A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis | Q38097556 |
| | Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis | Q39459295 |
| | The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. | Q43162409 |
| | Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation | Q43265365 |
| | Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. | Q43456267 |
| | Mutations and prognosis in primary myelofibrosis | Q44429606 |
| | Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). | Q44707716 |
| | Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting | Q45126468 |
| | Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type | Q47174502 |
| | Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk. | Q50534892 |
| | Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. | Q50857194 |
| | Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. | Q51023659 |
| | JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. | Q51811978 |
| | Improving survival trends in primary myelofibrosis: an international study. | Q53126695 |
| | Leukemia risk models in primary myelofibrosis: an International Working Group study. | Q53136481 |
| | Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. | Q53136705 |
| | Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. | Q53147067 |
| | Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. | Q53166045 |
| | EZH2 mutational status predicts poor survival in myelofibrosis. | Q54560112 |
| | Incidence and Risk Factors for Early Hepatotoxicity and Its Impact on Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation | Q60710980 |
| | A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). | Q61050093 |
| | Myelofibrosis with myeloid metaplasia | Q73712758 |
| | Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Resea | Q77363568 |
| | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 |
| | Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia | Q79817900 |
| | Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens | Q80262366 |
| | Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases | Q80607021 |
| | Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment | Q80866784 |
| | A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis | Q83388958 |
| | The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries | Q84065231 |
| | Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis | Q84271207 |
| | SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival | Q84962229 |
| P433 | issue | 2 | |
| P921 | main subject | myelofibrosis | Q1752571 |
| P304 | page(s) | 114-122 | |
| P577 | publication date | 2014-03-01 | |
| P1433 | published in | Current Opinion in Hematology | Q15757961 |
| P1476 | title | Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits? | |
| P478 | volume | 21 | |